Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.

Ryan C, Shore ND, Concepcion R.

Postgrad Med. 2013 Nov;125(6):114-6. doi: 10.3810/pgm.2013.11.2718.

PMID:
24200767
2.

A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.

Shore ND, Concepcion R, Barocas DA.

Hosp Pract (1995). 2013 Oct-Nov;41(4):78-80. doi: 10.3810/hp.2013.10.1083.

PMID:
24145592
3.

A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.

Taplin ME, Berry WR, Casey AM, Aslo A.

Hosp Pract (1995). 2013 Oct-Nov;41(4):81-2. doi: 10.3810/hp.2013.10.1084.

PMID:
24145593
4.

[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].

Basset V, Flamand V, Crouzet S, Ploussard G.

Prog Urol. 2013 Oct;23 Suppl 1:S44-8. doi: 10.1016/S1166-7087(13)70045-9. Review. French.

PMID:
24314738
5.

[Chemotherapy for CRPC].

Ozono S, Furuse H.

Nihon Rinsho. 2014 Dec;72(12):2170-3. Japanese.

PMID:
25518353
6.

Abiraterone acetate for the treatment of prostate cancer.

Ryan CJ, Cheng ML.

Expert Opin Pharmacother. 2013 Jan;14(1):91-6. doi: 10.1517/14656566.2013.745852. Epub 2012 Nov 30. Review.

PMID:
23199349
7.

Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.

Schmid S, Omlin A, Blum D, Strasser F, Gillessen S, Rothermundt C.

Ann Oncol. 2015 Nov;26(11):2221-47. doi: 10.1093/annonc/mdv326. Epub 2015 Jul 27. Review.

PMID:
26216388
8.

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.

Sternberg CN, Baskin-Bey ES, Watson M, Worsfold A, Rider A, Tombal B.

BMC Urol. 2013 Nov 9;13:58. doi: 10.1186/1471-2490-13-58.

9.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

10.

[Pathophysiology and therapy of castration-resistant prostate cancer].

Merseburger AS, Kuczyk MA, Wolff JM.

Urologe A. 2013 Feb;52(2):219-25. doi: 10.1007/s00120-012-3054-8. Review. German.

PMID:
23160609
11.

Castration-resistant prostate cancer: AUA Guideline.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.

J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9.

PMID:
23665272
12.

Towards random sequencing or precision medicine in castration-resistant prostate cancer?

Loriot Y, Fizazi K.

Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. Epub 2013 Sep 19. No abstract available.

PMID:
24075577
13.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
14.

[Corticotherapy in castration-resistant prostate cancer].

Lebdai S, Branchereau J, Robert G, De La Taille A, Bouchaert P.

Prog Urol. 2013 Oct;23 Suppl 1:S23-33. doi: 10.1016/S1166-7087(13)70043-5. Review. French.

PMID:
24314736
15.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.

PMID:
21315502
16.

[Evaluation and diagnosis for castration resistant prostate cancer: CRPC].

Kamoto T.

Nihon Rinsho. 2014 Dec;72(12):2103-7. Review. Japanese.

PMID:
25518341
17.

Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.

Du J, Yang Q, Chen XS, Tian J, Yao X.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1055-61. doi: 10.1007/s00280-013-2291-x. Epub 2013 Sep 17.

PMID:
24043138
18.

The role of abiraterone in the management of metastatic castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M.

Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37. doi: 10.1586/era.12.12. Review.

PMID:
22500680
19.

[Role of urologists in the era of new treatment modalities for CRPC in Japan].

Ozono S.

Gan To Kagaku Ryoho. 2014 Jul;41(7):823-6. Japanese.

PMID:
25131867
20.

Emerging drugs for prostate cancer.

Chung PH, Gayed BA, Thoreson GR, Raj GV.

Expert Opin Emerg Drugs. 2013 Dec;18(4):533-50. doi: 10.1517/14728214.2013.864635. Review.

PMID:
24274615

Supplemental Content

Support Center